Status:
WITHDRAWN
Is There a New Gold Standard for the Treatment of Obsessive-Compulsive Disorder?
Lead Sponsor:
University of Alberta
Conditions:
Obsessive-Compulsive Disorder
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Obsessive Compulsive Disorder is a highly debilitating condition with a lifetime prevalence of 2%-3%, and a notable percentage of patients (40-60%) have a partial or no response to medications. The pr...
Detailed Description
i. Purpose a) The purpose of this study is to compare and evaluate the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) by MagVenture and Deep Transcranial Magnetic Stimulation (DTMS) ...
Eligibility Criteria
Inclusion
- i. Outpatients ii. Men and women 18-70 years of age. iii. Patients diagnosed as suffering from OCD according to the BOCS and YBOCs. iv. Patients had an inadequate/intolerable response to SSRI, CBT (Exposure and Response Prevention) or both.
- v. Patient is capable and willing to provide informed consent, and their guardians is capable of providing informed consent.
- vi. Patient is able to adhere to the treatment schedule.
Exclusion
- i. Present suicidal risk is significant as assessed during the investigator's mental status exam and psychiatric interview.
- ii. Patient has a history of epilepsy or seizure (EXCEPT those therapeutically induced by ECT) or history of such in first-degree relatives.
- iii. Patient has an increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure, or history of significant head trauma with loss of consciousness for greater than or equal to 5 minutes.
- iv. Patient has a history of head injury necessitating cranial surgery or prolonged coma.
- v. Patient has ferromagnetic material in the head including the eyes and ears (outside the mouth) and body.
- vi. Patient has a history of significant hearing loss. vii. Patients with significant neurological disorder or insult including, but not limited to:
- Any condition likely to be associated with increased intracranial pressure
- Space occupying brain lesion
- History of cerebrovascular accident
- Transient ischemic attack within two years
- Cerebral aneurysm
- Dementia
- Parkinson's disease
- Huntington's chorea
- Multiple sclerosis
- Mini Mental State Exam score of less than or equal to 24 (for adult participants) viii. Patient has a history of substance abuse including alcohol use disorder within the past 6 months (except nicotine and caffeine).
- ix. Inadequate communication with the patient. x. Patient is currently participating in another clinical study or enrolled in another clinical study within 30 days prior to this study.
- xi. Patients who suffer from an unstable physical, systemic and metabolic disorder such as unstable blood pressure or acute, unstable cardiac disease.
- xii. Women who are pregnant or with suspected pregnancy
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04436952
Start Date
July 1 2020
End Date
July 1 2022
Last Update
July 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Envision Mind Care
Edmonton, Alberta, Canada, T6W 2Z8